News

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal condition driven by misfolded transthyretin (TTR) protein deposits in the heart muscle…

Details and patient eligibilityAboutThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in…

IntroductionAccording to Mordor Intelligence, the transthyretin amyloidosis treatment market size is expected to reach USD 7.05 billion in 2026 and is forecast to…

AccurKardia revealed it’s been granted U.S. Patent No. 12,620,488 for its proprietary machine learning-based system to identify cardiac amyloidosis from a standard…

INTRODUCTIONAcquired transthyretin amyloidosis (ATTR) represents a rare but recognized complication in recipients of domino liver transplants (DLT) from donors…

AbstractAimsTransthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-CM […

The cross-border transfer of machine learning models based on the International Classification of Diseases, 10th revision (ICD-10) for the identification of rare…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-…

There are substantial delays from the time of incident heart failure to a diagnosis of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to a new…

AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac AmyloidosisPatent establishes IP across all major amyloidosis subtypes and transforms the standard…